Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Neurotech International ( (AU:NTI) ).
Neurotech International has appointed Dr. Bonni Goldstein as Chief Medical Advisor USA, enhancing its strategic capabilities in cannabinoid-based therapies for paediatric neurological disorders. Dr. Goldstein’s extensive experience and network are expected to bolster Neurotech’s regulatory strategy and clinical advancement in the US, particularly as the company progresses NTI164 towards commercialisation. Her appointment is seen as a strong validation of Neurotech’s innovative approach and the potential of NTI164 in treating neurological conditions, increasing the company’s visibility and impact in the US market.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing therapies for paediatric neurological disorders. The company is advancing a broad-spectrum oral cannabinoid drug therapy called NTI164, which has shown promising results in clinical trials for conditions such as Autism Spectrum Disorder, PANDAS/PANS, and Rett Syndrome.
Average Trading Volume: 748,568
Technical Sentiment Signal: Sell
Current Market Cap: A$17.84M
See more insights into NTI stock on TipRanks’ Stock Analysis page.